Erenumab was approved by FDA in 2018 for
Erenumab belongs to a new class of drugs known as selective calcitonin gene-related peptide (CGRP) antagonists, which are used for the treatment of acute migraine attacks.
Phenylketonuria
Migraine
Hypeension
Glycogen storage disorders
All India exam